Study of Efficacy and Safety of Secukinumab in Japanese Patients With Active Ankylosing Spondylitis
Status:
Completed
Trial end date:
2018-05-16
Target enrollment:
Participant gender:
Summary
The purpose of this study was to assess the clinical efficacy, safety and tolerability of
secukinumab subcutaneous injections up to 52 weeks in Japanese patients with active AS
despite current or previous non-steroidal anti-inflammatory drugs (NSAIDs) and/or anti-tumor
necrosis factor (TNF) α therapy. Efficacy and safety data were used to support the
registration of secukinumab in Japan for the treatment of active AS.